Free tool
FAERS Monitor: Prograf
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 210115 or its brand name (Prograf, Tacrolimus). Reports on generic versions are filed under their own applications.
Reports
155,512
Serious
139,657
90% of reports
Hospitalization
62,496
Death reported
25,602
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use15,345
- drug ineffective10,482
- product use in unapproved indication6,396
- drug interaction6,373
- acute kidney injury6,111
- diarrhoea5,893
- transplant rejection4,902
- death4,875
- pyrexia4,864
- cytomegalovirus infection4,599
- pneumonia4,567
- toxicity to various agents3,914
- covid-193,893
- renal impairment3,617
- sepsis3,580
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 699 |
| 2005 | 875 |
| 2006 | 913 |
| 2007 | 1,485 |
| 2008 | 1,997 |
| 2009 | 2,169 |
| 2010 | 2,343 |
| 2011 | 3,918 |
| 2012 | 4,663 |
| 2013 | 3,853 |
| 2014 | 4,552 |
| 2015 | 5,030 |
| 2016 | 6,022 |
| 2017 | 8,087 |
| 2018 | 10,994 |
| 2019 | 10,666 |
| 2020 | 12,133 |
| 2021 | 11,473 |
| 2022 | 11,897 |
| 2023 | 13,254 |
| 2024 | 14,306 |
| 2025 | 14,189 |
| 2026 | 9,986 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,898,647 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| transplant rejectionSignal | 4,902 | 211.1 | 201.9 | 398,814 |
| cytomegalovirus infectionSignal | 4,599 | 51.3 | 49.6 | 164,349 |
| renal impairmentSignal | 3,617 | 6.0 | 5.8 | 14,611 |
| drug interactionSignal | 6,373 | 5.6 | 5.5 | 23,396 |
| acute kidney injurySignal | 6,111 | 5.6 | 5.4 | 22,234 |
| sepsisSignal | 3,580 | 4.5 | 4.3 | 9,320 |
| product use in unapproved indicationSignal | 6,396 | 3.6 | 3.5 | 11,584 |
| toxicity to various agentsSignal | 3,914 | 3.2 | 3.1 | 5,792 |
| covid-19Signal | 3,893 | 3.0 | 3.0 | 5,275 |
| off label useSignal | 15,345 | 2.4 | 2.4 | 12,775 |
| pneumonia | 4,567 | 1.9 | 1.9 | 2,018 |
| pyrexia | 4,864 | 1.9 | 1.9 | 2,127 |
| diarrhoea | 5,893 | 1.2 | 1.2 | 273 |
| drug ineffective | 10,482 | 1.1 | 1.1 | 60 |
| death | 4,875 | 0.8 | 0.7 | 368 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.